• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• Sen. Grassley Sends Letters To Wyeth, Medical Communications Firm Seeking Information Ab ...
  Wed, 17 December 2008
  Senate Finance Committee ranking member Chuck Grassley (R-Iowa) on Friday sent separate letters to Wyeth and
• New Roche Dual Target HIV-1 Test Approved For Use In European Union
  Wed, 17 December 2008
  Roche announced that its innovative dual-target HIV-1 test has received CE Mark certification, allowing it to be sold for clinical use in the European Union. The COBAS(R) AmpliPrep/COBAS(R) TaqMan(R) HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome. This ...
• QRxPharma Initiates Comparative Study For MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
  Wed, 17 December 2008
  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced initiation of a comparative study to evaluate the efficacy and safety profile of MoxDuoIR(TM) against eq ...
• DeCODE Discovers Common Genetic Variations Contributing To Low Bone Mineral Density And ...
  Wed, 17 December 2008
  Scientists from deCODE genetics (Nasdaq: DCGN) and colleagues from Australia and Denmark report the discovery of common single-letter variations (SNPs) in the human genome linked to low bone mineral density (BMD), the clinical measurement used to diagnose osteoporosis. deCODE had previously identified five sites in the geno ...
• Synvista Therapeutics Announces First Dosing Of SYI-2074 In Clinical Trial For Psoriasis
  Wed, 17 December 2008
  Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a 30-patient Phase 2 clinical trial of its proprietary topical GPx-mimetic, SYI-2074, in patients with psoriasis. The trial is planned to be a 28-day multi-center, randomized, double-blind, placebo controlled study to assess the efficacy of t ...
• Gilead Sciences Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
  Tue, 16 December 2008
  Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Tru ...
• Sanofi-Aventis And Bristol-Myers Squibb Prevail Before The U.S. Court Of Appeals For The ...
  Tue, 16 December 2008
  Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the U.S. Court of Appeals for the Federal Circuit has upheld the June 19, 2007 decision by the U.S. District Court for the Southern District of New York holding the U.S. patent 4,847,265 c ...
• Informa Unveils Scrip 100
  Mon, 15 December 2008
  Scrip World Pharmaceutical News has published today the 2009 edition of the Scrip 100 - its flagship annual analysis of the pharmaceutical industry, providing data, research and expert opinion on the performance, prospects and current state of the biopharmaceuticals market.
• RAD001 Shows Potential To Reverse Resistance To Herceptin(R) In Metastatic Breast Cancer ...
  Sun, 14 December 2008
  New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab) in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinito ...
• Wyeth Announces Positive Data From Phase 2 Study Of Neratinib In Advanced HER-2-Positive ...
  Sun, 14 December 2008
  Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced data from an open-label phase 2 clinical trial of neratinib (HKI-272) in women with advanced HER-2-positive breast cancer. These data suggest that neratinib has antitumor activity in patients with advanced breast cancer positive for the ErbB-2 receptor (also ...